Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERTU-SODIUM: Ertugliflozin in Heart Failure With Reduced Ejection Fraction
NCT05152940Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ertugliflozin in heart failure with reduced ejection fraction (HFrEF), sponsored by Icahn School of Medicine at Mount Sinai. Started Feb 2023; status: completed.
02
Drugs
ertugliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05152940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152940.